Speakers

WILLIAM ADAMS is a Partner at Knobbe Martens, where his primary focus is patent counseling and litigation in the biotechnology, pharmaceutical, and medical device fields.  William has been involved in numerous patent disputes on behalf of life sciences and pharmaceutical companies, and is co-chair...

More than 20 years of experience in pharmaceutical companies, with strong research, pre-clinical and clinical safety expertize in different therapeutic areas. For 10 years, acted as project/ team leader and laboratory head, leading various pre-clinical and clinical therapeutic...

Haider is a digital, sales and marketing leader, an international conference speaker, specialised on digital transformation and product launches within the healthcare industry especially pharma.Holding both a Master degree in Engineering and a Master degree in Marketing Strategy, he developed a...

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Düsseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M...

DR. SAMEER AWSARE is an Associate Executive Director for The Permanente Medical Group in charge of Pharmacy, Adult and Family Medicine, Mental Health, Risk Adjusted Coding, Revenue Cycle, Outside Medical Services, Pain Management and the Opioid Initiative.Dr. Awsare joined the Permanente Medical...

Carla C. Baan, PhD, is professor and head of the Nephrology & Transplantation Laboratory at Erasmus Medical Center, University Hospital Rotterdam, The Netherlands. Dr Baan obtained her doctorate from Erasmus University, The Netherlands.Her position involves the supervision of doctorate research ...

Marina joined Roche in 2010 and currently heads one of the Cancer Immunotherapy Departments at the Roche Innovation Center Zurich (RICZ). Marina and her team are dedicated to the characterization of the activity of different anti-cancer therapeutic agents including T-cell bispecific antibodies...

Martin obtained a PhD in Biochemistry from the University of Konstanz in a joint program with the University of Michigan. After postdoctoral training at the University of Washington, Martin joined Amunix Pharmaceuticals to work on long-acting protein therapeutics. In his current role at Roche, he...

Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena’s...

I obtained a BSc in Biochemisty and did a PhD in Biochemisty at the National Institute of Medical Research, University College London. I then went onto do a number of post-doctoral studies with Prof David Beach at University College London, Prof Ashok Venkitaraman at the University of Cambridge and ...

A Medical professional with specialization in M.D. Clinical Pharmacology with 18 years of Pharma/Biopharma experience; Currently working as Vice President & Head– Medical, Clinical & Regulatory affairs for Wockhardt , Mumbai ; Earlier worked for Intas Pharma Ltd (15 years ) & Alembic (2 ...

Dr. Barnum is the Director of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and Takeda Pharmaceuticals. ...

Sharon Barton is an Associate Director, Statistics Team Leader within Oncology Biometrics at AstraZeneca in Cambridge, UK.  She joined AstraZeneca in November 2017 and currently leads a team of statisticians based within the UK and US supporting early phase clinical development.  Prior to joining...

Amrik has a PhD in biochemistry/protein engineering from the University of Leicester after which he spent 6 years at the Institute of Biotechnology, Cambridge University investigating bacterial pathways involved with the metabolism of illicit drugs and high explosives. In 2002, Amrik joined...

Dr. Bateman is currently Scientific Associate Vice President and the Scientific Lead for Bioanalysis in the Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck & Co. where he has worked for over 21 years.  He is the co-founder of the Merck Smart Trials initiative aimed ...

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Dr Philip Beer is a physician scientist and precision oncology specialist who holds diverse roles across the healthcare, academic and commercial sectors, united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. Philip is currently working with the NHS...

Dr. Roger R. Beerli (CSO, NBE-Therapeutics AG) has over 20 years of experience in the discovery, engineering and preclinical development of antibody-based therapeutics. Before he joined NBE-Therapeutics AG, he led therapeutic antibody development programs at Cytos AG, Switzerland, and later at...

Stephen Beers joined the University of Southampton, Faculty of Medicine in 2002. His research group is interested in how antibodies work to result in tumour regression. Their research is currently focused on how host factors such as the tumour microenvironment and obesity/nutrition affect cancer...

Gustaf is an administrator / health economist with the Stockholm County Council, which is the regional authority responsible for providing health care in the Stockholm region. He coordinates the introduction of biosimilars in Stockholm. Before joining the Stockholm County Council four years ago he...

Mehdi Benchoufi is an Assistant Professor in Epidemiology in Clinical Epidemiology Center, at Hôtel Dieu Hospital, with Pure Mathematics and Computer Science background. His main interests are on the augmentation of healthcare by new technologies, and Open Science as an inclusive tool to improve...

Guillaume began his studies at the High Preparatory School in Biology in France, from which he holds MSc in Biotechnology in 2012. He worked four years for Novartis and UCB where he worked at the Center of Expertise for Biologics in Switzerland. Currently working as a Marie Curie Early stage...

Dr Krzysztof Bielikowicz is principal scientist in Analytical Development team, Process Sciences department at Glenmark Pharmaceuticals SA in La Chaux-de-Fonds (NE, Switzerland). Krzysztof joined Glenmark in 2016 and has been responsible for conceptualising and executing analytical development and...

Alain Bindels is an experienced Design Thinking facilitator, who leads an Innovation task force at Roche, supporting different business units to adopt innovation. He is interested in patient centric design of the healthcare industry, using new available technologies. He is applying the Design...

2016 PhD "Optimization of recombinant protein expression in insect cells" at the Helmholtz Center for Infection Research (Braunschweig, Germany)10.2016-09.2018 Head of the recombinant protein expression facility at the Rudolf Virchow Centre (Würzburg, Germany)since 10.2018 Habilitation at ...

Attilio Bondanza, formerly Head of Innovative Immunotherapies Unit and Professor at San Raffaele University Hospital (Milano, IT) has 20 years of experience in pre-clinical and clinical cell and gene therapy (H index: 31). He has contributed to the EU registration of Zalmoxis (HSV-TK suicide...

A physician by training and an expert in immunobiology and drug development, Ezio Bonvini is the Senior Vice President of Research and Chief Scientific Officer at MacroGenics, Inc., which he joined in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics...

Dr Otmane Boussif has over 25 year experience in developing biological modalities including monoclonal antibodies, recombinant proteins, vaccines and cell & gene therapy.He held several positions in R&D with increasing responsibilities and worked at various companies including...

Patrick Bulau is principal scientist leading a team performing physico-chemical analyses with special focus on mass spectrometric technologies at Roche Pharma Technical Development in Penzberg, Germany. In addition to his responsibility for the analytics of drug substance development products he is ...

Ryan founded Oxford Genetics in 2011 to develop technologies that streamline the discovery, development and manufacture of complex biologics, including cell, gene and protein therapies. He has led the company as CEO for the last 8 years and is passionate about developing platform technologies that...

Andrei Chapoval is currently a Director of Russian-American Anti-Cancer Center at Altai State University and Associate Professor at Center for Innovation in Medicine, Biodesign Institute of Arizona State University. He obtained his PhD in Immunology from Institute for Human Morphology...

Dr Veeren Chauhan is a Research Fellow in the Advanced Materials & Healthcare Technologies (AMHT) division at the School of Pharmacy, University of Nottingham. He is currently working as part of the EPSRC Future Targeted Healthcare Manufacturing Hub, aiming to develop transformative solutions...

Dr Andre Choo leads the Antibody Discovery Platform at Bioprocessing Technology Institute (BTI) focusing on the discovery of new biologics against stem cells and cancer cells.  He was also responsible for the discovery of a first-in-class antibody that kills embryonic stem cells and improves the...

Partha Chowdhury is Senior Director in Sanofi Biologics Research, US. He joined Sanofi in 2017 and leads antibody discovery and technology development activities in Biologics discovery, research and development. He has been involved with antibody discovery, engineering and technology development...

•    PhD MD Hanne Rolighed Christensen•    Head of Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark•    Member of the National Council of Medicine•    Vice chairman of the Drug Committee, Capital Region•    Chairman of the association of the 5 Regional ...

Dr Vijay Chudasama (VC) is a Reader in the Chemistry department at University College London. He has won multiple prestigious prizes and awards (departmental, faculty, national and international) throughout his academic career such as the UCL Faculty of Mathematical and Physical Sciences Medal...

Steve Coats serves as AstraZeneca/MedImmune’s VP R&D and Product Development Team Leader. His work focuses on interacting with external investigators to initiate clinical trials that are investigator led at academic institutes. Dr. Coats is also a product development team leader where he leads...

Dr. Coats earned his bachelor’s degree in zoology from the University of New Hampshire in 1985. Following his undergraduate degree, he earned his Ph.D. in molecular and cell Biology in 1993 at Vanderbilt University’s Department of Cell Biology. The focus of his graduate work was on the role that...

In 2004 I have received my Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy). After a post-doc in cancer immunotherapy at the Ludwig Institute for Cancer Research (Lausanne branch) and later at Cytos Biotechnology (Zurich) I have joined the Roche...

Robin Curtis joined the Chemical Engineering and Analytical Science School at University of Manchester in 2003.  Previously he did his PhD at the University of California at Berkeley and post doctoral training at University of California Los Angeles and Rice University.  His current research is...

I received a Engineer & Master degree in Antibody and Cell Engineering from Reims University in 2004.I have ~15 years of relevant industrial experience: Sanofi (2006-present), Centelion formerly Gencell fully owned by Sanofi (2004-2006). My accomplishments in antibody drug development include...

Eva Dahlén, Ph.D., is a life science professional with approximately 20 years of experience from the life science sector. Her current position is as Senior Director, Business Development at Alligator Bioscience. In this capacity, her responsibilities include business development and business...

Nissim Darvish, M.D., Ph.D., is a Senior Managing Director. Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner...

After starting her career in the field of molecular biology and tissue culture, Madhu went on to focus on molecular histopathology research, supporting biomarker development for Barrett's Oesophagus at the MRC cancer cell unit in Cambridge.  Whilst at the MRC toxicology unit, University of...

Following a degree in Biology at the University of Padua, Carmela joined Professor Vincenzo Bronte’s group in 2002 to study for a PhD. Her studies focussed on myeloid derived suppressor cells (MDSCs), a heterogeneous grouping of myeloid lineage cells that suppress immune responses, and which are...

Annick has over 15 years of experience in both pharma and academia in Australia, the USA, UK, Belgium and the Netherlands. She was trained as a neuroscientist (University of Amsterdam, NL) and acquired her PhD in Pharmacology at Utrecht University (NL). Her experience in assay development started...

Dr. Ruud de Wildt has more than 20 years of experience within the Biotech and Biopharmaceutical industry. His teams have delivered many therapeutic candidate molecules across several therapeutic areas including oncology, respiratory, infectious diseases and the immunology field. This includes...

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary XenoMouse platform technology. John joined ...

Gundo Diedrich received his Ph.D. in Chemistry from the Max-Planck Institute for Molecular Genetics in Berlin. He completed his postdoctoral training in immunology at Yale University, and worked as a Research Scientist in antibody discovery at Targeted Molecules, diaDexus, and Medimmune. In...

Surjit Dixit, Ph.D. has been with Zymeworks Inc. since 2007 and currently serves as its Vice President, Technology. As the field of drug discovery has expanded from small molecules to protein therapeutics, Zymeworks has been at the forefront employing rational protein engineering to complement...

Peter has a broad background spanning engineering and biology and specialises in companies that breakdown barriers to progress through innovative assay, instrument and software design. Working both as a consultant and with companies such as Molecular Devices, Essen and IntelliCyt Peter has enjoyed...

Maggie achieved her BSc pharmacy at Heriot Watt University, Edinburgh, and a diploma in clinical pharmacy from Strathclyde University in 1991. She has many years of experience as a hospital clinical pharmacist primarily in Scotland. She was Chief Pharmacist in Edinburgh in both the adult (West...

Before joining the EPO, Dr. Domingues completed a PhD degree in Protein Engineering at the European Molecular Biology Laboratory in Heidelberg in collaboration with the University of Utrecht, followed by post-doctoral work. She joined the EPO in October 2000 and worked as a Patent Examiner in the...

As R&D Director of GEROPHARM Roman establishing product development of the company’s portfolio.Joined GEROPHARM as a head of clinical trials department in Oct 2016. Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III...

Dr. Birgit Dreier has been Senior Scientist in the group of Prof. Dr. A. Plückthun at the Department of Biochemistry, University of Zurich, for more than 10 years and is responsible for the organization, optimization and selection of DARPins (Designed Ankyrin Repeat Proteins) and other scaffold...

Jen has worked for GSK for over 10 years and in this time has gained experience working with a range of antibody formats including mAbs, dAbs, dAb fusions and mAb-dAbs. Recently her work has focused specifically on developability, developing screens for solubility of mAbs targeting high...

Dr Carolyn Edwards is a Principal Scientist and Project Leader at Crescendo Biologics, a company developing Humabody® VH domain antibodies for cancer. She is Pharmacology Lead in a drug development program for a novel bispecific tumour-targeted T-cell enhancer. Dr Edwards also leads a team of...

Sybille Eibert (PhD in immunology) has more than 15 years of experience in regulatory medical writing and more recently in clinical data transparency. She currently works as Associate Director Transparency & Disclosure at Teva in Switzerland. There, she focuses on the implementation of clinical ...

Meltem Elitas is a faculty member at Sabanci University Mechatronics Program since 2015. She was a postdoctoral research associate in the Bioengineering Department at Yale University, Connecticut, US. She worked with Prof. Rong Fan, developed microfluidic artificial tumor microenvironment assays to ...

Patient Engagement in Research Coordinator at Sant Joan de Déu Chidren’s Hospital (Spain). She has long experience in the field of the involvement of patients and families in research initiatives. She has also a personal story as a caregiver and patient advocate because is the sister of a young...

Stefan Ewert, Ph.D. joined Novartis in 2004 and holds the position of a Senior Investigator within the NIBR Biologics Center. He is responsible for antibody phage display selections done in Basel. Before joining Novartis he was instrumental in developing ESBATech’s scFv-based key technology. During ...

During his Ph.D., Lorenzo worked on a variety of translational topics regarding cancer immunotherapy, including the use of repertoire sequencing data as a tool to identify therapy-induced changes in patients treated with immunotherapeutic intervention strategies. In his current role as project...

Georg Fey. Degrees in physics and biochemistry. Post-doctoral training in tumor virology and molecular genetics. Team leader, Swiss Cancer Research Institute, Lausanne, CH. Lab Chief, Dept. of Immunology, Scripps Research Institute, La Jolla, CA, USA. Chairman of Genetics, University of...

Dr. Romano is currently working as Associate Professor in Biochemistry at the University of Naples “Federico II”. She received her Doctoral degree on Medicine and Surgery from the University of  Naples “Federico II”. She completed her Masters in Oncology and Immunology at the Universities of Naples ...

Figini has been involved in antibody production, characterization and engineering from the beginning of her career starting with the classic hybridoma technology and chimerization up to isolation of human antibodies from phage display library a revolutionary technology discovered in the early...

Bruno Filippi is a senior research associate in mammalian cell engineering, genetic reporter systems and antibody discovery at the Zürcher Hochschule für Angewandte Wissenschaften in Wädenswil, Switzerland. In this position, he is responsible for the acquisition, financing and supervision of...

Jonny Finlay is the CEO of UltraHuman, an antibody drug discovery biotech in the UK that is developing a series of therapeutics for inflammation and oncology. Prior to co-founding UltraHuman, Jonny led research teams in Biologics Discovery at Pfizer and Wyeth, and carried out postdoctoral research...

Nicolas Fischer obtained a PhD in Biology from the Department of Molecular Biology University of Geneva on the structure and function of photosynthetic complexes. As a postdoctoral fellow he joined the Group of Sir Greg Winter at the MRC Department of Molecular Biology in Cambridge UK to study...

Christian has a degree and a PhD in Chemistry from the University of Düsseldorf, Germany. He then joined Bruker in 1999 in the NMR Software Development group. After working on mixture analysis products, he moved into the MRS Application Development. Now he is Product Manager of AssureNMR and...

Simon Friedensohn is a Ph.D. candidate in Sai Reddy’s Laboratory of Systems and Synthetic Immunology at ETH Zurich. His research work focuses on developing both experimental as well as computational methods for high-throughput immune repertoire sequencing. He holds a B.Sc. and M.Sc. in...

Dr. Tim Fugmann received his PhD from the ETH Zurich in 2010 developing and applying proteomics methods for the discovery of disease-relevant biomarkers and targets for pharmaceutical intervention. For eight years, he was heading the target and biomarker discovery group at the Swiss-Italian...

Patrick Garidel is currently employed as Head of Pharmaceutical and Protein Science at Boehringer Ingelheim Pharma GmbH & Co. KG. His activities are focused on the development biologics from the downstream process to drug product (liquid and solid formulations, freeze-drying). His expertise...

Hans-Peter has over 20 years of research and development experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies. He has been leading Pfizer’s Bioconjugates division as CSO, overseeing Pfizer’ s efforts in...

Tariq Ghayur received his Ph.D in Immunology from McGill University, Montreal, Canada and did his post-doctoral training at McGill and Dana Farber Cancer Institute. He joined AbbVie Inc. in 1990. Tariq has worked on both small molecule and therapeutic antibody discovery programs; led two...

Florian Gillet joined Novartis Pharma AG in 2010. His initial focus was on process development R&D to develop purification processes for biologicals supporting early and late phase programs. Since 2015 he has focused on high throughput process development and, at present, is leading the...

Marco Gobbi got his M.Sc. degree in Pharmacy at the University of  Milan in 1989.  After a fellowship spent in the Dept. of Pharmacology of the School of Pharmacy, University of London, he started his research activities in the laboratory of Neuropharmacology at the "Mario Negri"...

Since 2012 Maria Gonzalez-Pajuelo is co-founder and Chief Scientific Officer at FairJourney Biologics, a company that provides fast and high quality solutions for monoclonal antibodies needs. Maria initiated her career in the antibody field in 2006 at Ablynx, where she worked on the identification...

Ulf Grawunder is a Biotech entrepreneur with more than 15 years in the Biotech industry. He is CEO of NBE-Therapeutics which he founded in 2012. Prior to that, Ulf was co-founder of 4-Antibody, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as...

Emma is Head of Clinical Trials at the MS Society. She is responsible for developing and supporting the MS Society’s growing portfolio of clinical trials; collaborating with national and international funders (charity, government, other) to secure funding for MS clinical trials, the UK MS Clinical...

Dr. Greenberg leads a multi-disciplinary research and early development team delivering unique therapeutics derived from the immune repertoires of elite responder patients in multiple indications. Dr. Greenberg previously held positions as Senior Vice President for Translational Medicine at...

Uwe Gudat received his medical degree from the University of Marburg, Germany. He is licensed in internal medicine and diabetology as a sub-speciality, training under Michael Berger in Düsseldorf Germany. Uwe Gudat joined the pharmaceutical industry in 1995 with Eli Lilly and since then has held...

I am currently Chief Scientific Officer (CSO) at GeoVax, awarded as the Best Biotech in Vaccine Congress VIE award in 2018. Our leading vaccine efforts include our clinical stage clade B HIV vaccine, Zika, hemorrhagic fevers including Ebola, Sudan, Marburg, and Lassa fever, malaria as well as...

Dr. Guo is the CSO and co-founder of I-MAB.  Previously Taylor worked in GSK Neuroinflammation unit for 8 years, where he led 3 small molecule and 2 protein drug discovery programs, gaining a wide range of experience for making differentiated medicines.  He is particularly keen on developing facile ...

Christian P. R. Hackenberger completed his graduate studies in chemistry at the universities of Freiburg and UW Madison and his doctoral studies in 2003 at the RWTH Aachen. After a postdoctoral position at MIT with Barbara Imperiali, he started his own group at the Freie Universität Berlin in 2005...

Dr Karin Hägerbrand earned her Ph. D. in 2015 at Lund University working with the immunobiology of dendritic cell and T cell interactions. She joined Alligator Bioscience the same year as a scientist establishing immuno- and bioassays within Preclinical Development of immune-modulatory...

Eric Halioua is a serial entrepreneur with strong managerial, technological, fund-raising and deal-making experience. Eric Halioua is President and CEO of PDC*line Pharma a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid...

Prior to Singapore Biotech, Dr. Hamedifar was the CEO of CinnaGen for 14 years. She was the founder of CinnaGen Group as well as CinnaGen’s seven sister companies. Under her leadership, she transformed the company from a diagnostic manufacturer to a global biopharmaceutical company, increasing...

Brenda Hann is the Director of Clinical Research Operations in the Stanford Cancer Clinical Trials Office at Stanford Cancer Institute.  The Cancer Clinical Trials Office provides central coordination and oversight of clinical staff to ensure consistent processes, regulatory compliance and...

As Director of Pharmacy, Matt works to monitor, evaluate, and improve the pharmacy plan performance of the Employers Health $1 billion PBM group purchasing programs with CVS Health, OptumRx and EnvisionRx. He works proactively with the organization’s more than 250 member employers to provide...

Guy joined Isogenica as CSO in 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development. At Isogenica, he leads the internal technology and product development, as well as drive scientific interactions...

Oliver Hill joined Apogenix in March 2006. He is an expert for protein engineering and protein expression technologies. Prior to his position at Apogenix, he headed the protein expression and purification group at Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany) from 1999 to 2006. At...

Rob Holgate has led Abzena’s Discovery and Protein Engineering team for 4 years. His primary role is to oversee and deliver antibody discovery, affinity maturation, humanisation and other protein optimization projects for Abzena’s clients. Rob previously was a team leader at Medimmune following his ...

Dr. Soraya Hölper works as a Lab Head for Mass Spectrometry for Sanofi in Frankfurt am Main. She is acquainted with the analysis of complex therapeutic antibodies within the Biologics Research division. After studying biochemistry at the Goethe University of Frankfurt am Main, Soraya did her...

Dr. Yue Huang graduated from Beijing Medical University, China, then obtained his PhD from University of Minnesota, USA.  He also completed an executive MBA from Swiss Business School (SBS) in Switzerland. Dr. Huang has 17+ years of pharmaceutical industry experience, with specialties in the...

Caroline initially studied Biochemistry before specialising in Immunology during her PhD. Her thesis focused on developing methods for the production of antigen specific regulatory T cells using lentiviral gene transfer with the aim to treat autoimmunity.  In 2017 she joined the CAR mechanics group ...

Dr. Michael Humbert is the Laboratory Director and co-founder of NTxBio located in Santa Fe, New Mexico.  He is a co-inventor of NTxpressTM.   Michael has world-class expertise in microbiology and virology, developed Phage Display techniques as faculty at the Dana Faber Cancer Institute, identified ...

An innovation, multi award-winning Clinical Operations and Consulting Expert with extensive experience and skills gained from international global assignments.  A blockchain advocate and patient engagement thought leader with over 17 years in the NHS on commission by the DOH and in Industry...

Dirk Jäger is the Managing and Medical Director of the National Center for Tumor Diseases (NCT) Heidelberg, Head of the Medical Oncology Department at the Heidelberg University Medical Center, and is Head of the Clinical Cooperation Unit Applied Tumor-Immunity at the German Cancer Research Center...

Arshad Jamil is a senior Indian Patent Attorney with extensive experience in the legal and IP rights fields. Arshad is the chief IP counsel and global head of IP rights at Biocon Biologics, where he is responsible for the company’s patent and trademark filings and policy, and handling Global...

Faiza Javaid received a First class honours MSci degree in Biochemistry from University College London (UCL), during which she was awarded the Plimmer Prize for Biochemistry (2014) and was twice a Dean's list commender. In 2016, she joined the Wellcome Trust 4 year Interdisciplinary...

Following my PhD in Chemistry I moved to the Medical School (Birmingham) to initiate research on the structure and function of antibody molecules. Studies of the four human IgG subclasses revealed the profound impact that glycosylation has on structure and mechanisms of action, in vitro and in...

Martina completed her PhD in Medicinal Chemistry at the Karolinska Institute, before working as a Researcher at Roche Process Research and Supply unit, of the pre-clinical chemistry manufacturing controls department. She then went on to a role as a Senior Scientist at Novartis NBE Pharmaceutical...

Dr. Xiaona Jing (Director Global CMC & Pharmaceutical Development, NBE-Therapeutics AG), has managed multiple biopharmaceutical CMC projects various from early clinical to the commercial stage, with focus on innovative oncology products such as antibody and ADC.She is experienced in...

Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003.  Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently...

Colette has been part of Crescendo Biologics since 2012. She is responsible for the proprietary mouse platform and early discovery activities in Crescendo’s Humabody discovery pipeline.  Colette joined Crescendo from MedImmune where she was in the Department of Antibody Discovery and Protein...

Having spent nearly a decade in clinical research working for the National Health Service, Academia, the Institute for Health Research an now Pharma I have gained a vast knowledge of many of the sectors providing input into clinical trials within the UK. I have a lot of experience in managing study ...

Founded in October 2016 by Carine MOREL, Sylvain JULIEN and Geoffroy DE BETTIGNIES, e-Zyvec is a Biotech company devised by scientists to serve scientists. Rather to provide another service of ‘customized’ DNA molecules to biologists, we aim to offer an efficient and innovative partnership in...

Dr. Jennifer Jung works as Lab Head for Mass Spectrometry for Sanofi in Frankfurt am Main. She is analyzing therapeutic proteins within the Biologics Research division using mass spectrometry. She started her scientific career by studying biochemistry at the Goethe University in Frankfurt am...

Meelis Kadaja is active in the development and commercialization of technologies for biological therapeutics, antibodies, immunoassays and gene therapy. His previous research areas have been DNA viruses and adult tissue specific stem cells. He received MBA and Ph.D in the University of...

Maud Kamal, PhD is the scientific manager of the department of Drug Development and Innovation at Institut CurieShe manages and coordinates precision medicine and European projects at Institut Curie where she is also in charge of the scientific management of the Molecular Tumour Board. She is...

Dr. Hélène Kaplon completed a PharmD at the University of Lille in 2014. Since 2011, she has co-authored Acthera, a guide of Therapeutic Antibodies approved in the European Union written for pharmacy students and pursued her career in the immuno-oncology field. Beginning 2015, she started a PhD in...

Project manager of the International Clinical Trials Registry Platform (ICTRP) in the World Health Organization since 2011, expert in clinical trials database design, clinical trials registration & results and ethics committees information systems. Member of several international working groups ...

Academic career2009-2012            Undergraduate studies with a B. Sc. In Chemistry                                Humboldt-Universtiät zu Berlin2012-2014            Graduate studies with a M. Sc. In Chemistry                                Humboldt-Universtiät zu Berlin2014-2018          ...

Andreas is co-founded Anaveon in April 2018, and previously was the Director of Autoimmunity, Transplantation & Inflammation, Novartis Institutes of  Biomedical Research, Basel Big Pharma experience in the discovery and development of immunomodulating drugs (26 years) Extensive BD&L...

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

Lisa Kinsella is Head Legal Biologics, Cell & Gene at Novartis Technical Operations, and provides legal support for all aspects of biologics and advanced therapies manufacturing, supply chain, quality and technical development.  Lisa joined Novartis in 2012 and has held positions of increasing...

Linda Klauss holds a position as Field Application Scientist at Gyros Protein Technologies, based in Uppsala, Sweden. Gyros is a biotechnology company that develops, produces and provides a complete bioanalytical system for protein quantification based on immunoassays. Linda joined the company in...

Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific...

Cecilie Knudsen is an industrial PhD student at the Tropical Pharmacology and Biotherapeutics Lab at the Technical University of Denmark and at BioPorto Diagnostics A/S. She is specialised in toxinology, antibody discovery, antivenom, and diagnostics, and is a co-founder of the start-up VenomAid...

Dr. Jiri Kovarik has more than 15 years of experience in drug R&D at the Novartis Institutes for Biomedical Research with focus on the generation of therapeutic antibodies for the treatment of inflammatory/auto-immune diseases. Before working in industry, his scientific activities included the...

The research of Peter Kristensen is centered on the technical development and application of methods that allow Darwinian evolution of proteins using directed evolution technologies. The main scientific contributions have more specifically been in the area of recombinant antibodies and methods of...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research in Japan and later in Denmark. For the last 15 years Dan has been working with analytical...

Dr. Anne Månsson Kvarnhammar earned her PhD 2009 at Lund University, Sweden, working on the immune response in allergic rhinitis. This area was further pursued during a postdoc position at Karolinska institutet. In 2012, Dr. Kvarnhammar joined Novo Nordisk, Denmark, working with developing models...

Dr. Lamb is scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus Therapeutics.  As a transplant immunologist with 27 years’ experience in clinical-translational immunotherapy research, he is responsible for first describing the association between relapse-free...

Dr. Lantto is a Project Director at Symphogen A/S, a Danish clinical late-stage antibody oncology-focused company. Dr. Lantto holds a Ph.D. in Immunotechnology from Lund University, Sweden, where he studied antibody evolution and repertoire development. Dr. Lantto has more than 20 years of...

Heinz Läubli is a physician scientist with clinical training and a specialisation in Medical Oncology. He is a senior attending physician at the University Hospital in Basel, Head of a clinical research group and Head of Glycobiology Research in the Cancer Immunology Laboratory in Basel. His...

Associate Professor Andreas Hougaard Laustsen heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine, Technical University of Denmark. He is specialized in antibody discovery, toxinology, antivenom, and neglected tropical diseases. Andreas is an Advisor to the WHO’s...

Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He is a skillful immunologist, with many years of teaching and research expertise on gastrointestinal complications ...

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 ...

Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. She became associate professor and head of the immunotherapy group of the University Medical Center in Utrecht in 2006, and head of the UMAB facility in 2012. She has co-authored more than 100...

Xiaonan Li studied chemistry in PKU (China), holds a Ph.D. from Delft University of Technology (Netherlands) with specializations in Bio-separation Technology and has over 10-year experience in protein biochemistry. Currently, he is the lead scientist in the downstream processing department at...

John Löfblom is associate professor at KTH Royal Institute of Technology. His current research focus is on method development for directed evolution of affinity proteins, proteases and aggregation inhibitors as well as engineering of small affinity proteins into multimeric formats for new modes of...

Thorsten Lorenz studied Biochemistry at the University of Bochum in Germany. He performed his PhD work at the Max Planck Institute for Medical Research in Heidelberg and afterwards joined Novartis as postdoctoral fellow. In 2011, he took the lead for the buildup of a laboratory for protein...

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, a clinical stage biotech company with innovative antibody discovery and engineering technologies. By utilizing its proprietary Dynamic Precision Library Platform (DPL) and SAFEbody™ technologies, Adagene is showcasing its...

Jörg Mahlich is Head of Health Economics and Outcomes Research at Janssen pharmaceutical companies of Johnson and Johnson in Germany. In addition, he is Lecturer of Health Economics at the Economics Department of the University of Vienna and research affiliate at the Düsseldorf Institute for...

Johannes got his Master’s Degree in Biology from the University of Freiburg, Germany and then moved to Canada for a PhD in Biochemistry. After that, Johannes worked in a German software company as a programmer and product manager. He then decided to combine the science training with his advanced...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

My interest in health and science led me to pursue a doctoral degree in Immunology, a field that I find fascinating. I initiated my scientific carrier studying the relationship between hormones and the immune system. Following the completion of my PhD studies I became interested in neuroimmunology...

David is currently a Principal Scientist at Distributed Bio with a focus on library technologies, affinity maturation, and next generation sequencing. Previously, he was senior microbiologist at Silliker (now BioMerieux), focusing on Salmonella and Listeria serology. David received his bachelor in...

Lamine is SVP & Head of Glenmark Biotherapeutics. Prior to joining Glenmark, Lamine held several leadership positions in the USA at Boehringer Ingelheim, Genomics Institute of Novartis Research Foundation (GNF), Novartis Vaccines and Centocor (Janssen) where he led and advanced several...

Christoph joined the European Molecular Biology Laboratory in Heidelberg, Germany, as a Principal Investigator in 2010, focusing on microfluidic technology for HTS and genomics. His lab is particularly interested in the development of droplet-based microfluidics for cell-based screens. Christoph is ...

Derek Mason worked as a process engineer in Denver, Colorado for 3 years before moving to Basel, Switzerland in 2015. Currently, he is finishing his PhD in the Laboratory for Systems and Synthetic Immunology at ETH Zurich’s Department of Biosystems Science and Engineering. Intrigued by recent...

Ali Mohamed, PhD, Vice President, CMC, Immatics US Inc. Formerly the senior director of manufacturing operations/ manufacturing development at Caladrius PCT (Now Hitachi Chemical Advanced Therapeutics Solutions). Dr. Mohamed has nearly 20 years of experience in process development and GMP...

Study of Biology in Bochum, GermanyPhD in Immunology/Allergy Research, Borstel, GermanyPost Doc in Cambridge, UK at the Babraham Institute with M. Brüggemann establishing transgenic mice expressing fully human antibodiesScientist in Cambridge, UK at the Babraham Institute with...

Following a PhD in Molecular Biology from the National University of Ireland, Galway in 2009, Thomas joined the British Heart Foundation Centre for Research Excellence at Kings College London, where he worked on signalling mechanisms involved in the differentiation of stem cells to the...

Aditya completed his doctoral studies at the University of Toronto, Canada, department of Medical Biophysics. He joined the Department of Immunology at Genentech as a post-doctoral fellow in the lab of Dr. Menno van Lookeren Campagne in 2011. Focusing on human genetics and the contribution of...

Dario Neri was born in Rome on 1 May 1963.. He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral...

Christiane has spent 12+ years in medicines, tissue, cell and gene therapy regulation. For the last 8 years she has worked at the MHRA, the UK’s medicine regulator, where she has assessed all classes of biological medicines at both UK and EU level and acted as the UK representative at the European...

Dr Zoe Nilsson is the Global Product Marketing Manager for Sphere Fluidics. Zoe has a BSc, MPhil and PhD in Neuroscience and Cell Biology from the University of St Andrews, UK. Zoe works closely with the R&D team to develop new features of Cyto-Mine® and novel assay reagent kits to help...

Johan Nilvebrant received his PhD in 2012 at the Royal Institute of Technology, Stockholm, Sweden. He was a postdoc with Sachdev Sidhu at the University of Toronto where he worked on new single-domain antibody library designs and ligand-mimicking antibodies. His current research focuses on protein- ...

Ahuva Nissim graduated in Molecular Immunology in Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed a phage display semi-synthetic human antibody library which has...

Dr. Natko Nuber is a Group head in Novartis Biologics R&D in Basel, Switzerland. He originates in Croatia where he received his M.Sc. in Molecular Biology at the University of Zagreb. Realizing his interest in applied science and especially immunology he moved to Switzerland where he obtained a ...

After a career in nursing and hospital management I took early retirement to allow me to develop further my interest in clinical trials. In particular I believe that there is a widespread lack of research awareness in the general population, and many barriers that prevent patients enrolling in a...

Senior Research Nurse Albany House Medical Centre   I have been involved in Primary Care research since 1999 developing our unit from a single investigator to our award winning team of nine staff. I mentor less experienced sites and have delivered workshops supporting staff new...

My research group is focused on protein engineering of calcium binding proteins for biotechnological applications. We apply structural biology analysis, proteomics tools and biophysical methods to develop new technology and our work is aimed at improving the molecular toolbox available to...

Christian Ohmann performed his university examination (1976) and graduation in mathematics together with an interim examination in medicine (1984). This was followed by a habilitation in Theoretical Surgery in 1997 and a professorship in 1993 at the Heinrich-Heine-University in...

Benjamí Oller-Salvia is Assistant Professor at IQS School of Engineering – Ramon Llull University in Barcelona (Spain). He obtained his PhD at the University of Barcelona, conducting research in Prof. Ernest Giralt’s laboratory at the Institute for Research in Biomedicine (IRB Barcelona). His PhD...

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug...

Mareike Ostertag has extensive experience in the pharmaceutical industry. In over 16 years with Novartis, Dr. Ostertag held different roles with increasing responsibility within the company as well as with external industry- and non-industry partners. Roles included Technical Marketing, Global...

Tanja holds a PhD in Neurosciences from the University of Montréal (Canada). She then moved to Paris to pursue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and...

Raj is a trained Medical Doctor from Australia & Health Care Entrepreneur with close to 2 decades of experience in Strategies & Partnerships, Technologies and Product Management. He had the pleasure of working with tens of Global Enterprises in the space of Consumer Health Care, Device...

I am a Sr. Scientist in the Immunology Discovery group at Genentech Inc. in South San Francisco, Ca. I received my PhD in Immunology from Washington University in St. Louis from the laboratory of Dr. Andrew Chan. My thesis work identified a role for the adapter protein, BLNK, in murine and human B...

Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor.After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and...

Prof. Paul W.H.I. Parren, (Lava therapeutics and Leiden University Medical Center, the Netherlands) is dedicated to translate antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren studied Biology at the University of Amsterdam where he obtained an...

Sue has a PhD in Human Cancer Genetics and had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. Since 1998 she specialized in Applied Health Research, Clinical Trials and...

Richard Peck studied medicine in the USA and obtained a Doctor of Philosophy from the University of Tennessee. Following a Post-Doc at the Biozentrum of the University of Basel (medical virology, molecular biology), he was employed by F. Hoffmann LaRoche, Basel as International Regulatory Affairs...

Thomas Pillow received his Ph.D from Stanford University in organic chemistry under the direction of Professor Paul Wender. Upon graduation he moved to Genentech in 2009 where he is currently a senior scientist in the discovery chemistry department leading Genentech’s effort on antibody-drug...

a long-standing international patient advocate promoting the rights of patients at both national and international levels.  A member of several patient advocacy movements and organizations like IAPO (International Alliance of Patient Organizations) and EPF (European Patients Forum). She has...

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or ...

Dr. Anne Poupon is Senior Scientist at the CNRS, heading the group Biology and Bioinformatics of Signalling Systems. After MS degrees in Biochemistry and in Mathematics, she has obtained a PhD thesis on the conservation of hydrophobicity in globular proteins. Since then she has been developing...

Senior clinical research professional and project manager with versatile drug development and clinical research expertise. Interested in clinical research innovation and patient centricity. Strategic adviser for start-up companies and independent expert at the European Commission.

Christophe is responsible for directing and advancing the development of Oncorus’ next generation oncolytic viruses. An industry veteran, Christophe has nearly two decades drug discovery experience in immuno-oncology and a successful track record of building portfolio from target identification...

Dr. Quintás joined TCR² in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás was the clinical development head of the Cell & Gene Therapies Unit...

Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer working at the life science, engineering and commercial interfaces and his research focuses on the bioprocessing, automation and biomanufacture of...

Dr. Ulrich Rant received his PhD in biophysics (summa cum laude) from the Technical University Munich, Germany, in 2005. After a PostDoc at TU Munich and a research stay at the Fujitsu Laboratories Ltd., Japan, he became a group leader at TU Munich in 2007. Uli was awarded a Carl-von-Linde...

Alexander Rau holds a master’s degree in Technical Biology from the University of Stuttgart, and he is a PhD student at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany. His research interest focuses on the development of multivalent and bispecific antibodies and their ...

Sai Reddy is an Associate Professor in the Department of Biosystems Science & Engineering, ETH Zurich, Switzerland. His research group uses methods in systems and synthetic biology to study and manipulate immune responses for applications in biotechnology, vaccination, and immunotherapy. Sai...

Carsten Reinhardt has extensive experience in translational development as well as in early and late-stage clinical trial design. Under his leadership multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man...

Nina is a Senior Scientist at Molecular Partners since beginning of 2018.  In her role, she supports the development of novel immune cell engagers based on Molecular Partner’s proprietary DARPin® Technology. During her academic career, Nina pursued her interest in cancer genetics and tumor...

Dr. Nicolò Rigamonti received his Master degree in Molecular Biotechnology from the Milano-Bicocca University. He performed his master thesis at the Royal Institute of Technology (Stockholm), developing an affibody-based strategy for breast tumors. During his PhD studies in tumor...

Following studies in molecular biology and biochemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Roesli performed his PhD thesis in the lab of Prof. Dario Neri at the same university. After the subsequent PostDoc period, he led his own research group on...

Diego Rosselli is a Colombian neurologist. He started his academic career in the field of basic and applied neuroscience, after training at London’s Institute of Psychiatry. He also has a Master's Degree in Education from Harvard University and a Master’s, in Health Policy, from the London...

Karsten Roth leads the clinical development and pharmacovigilance teams at Mundipharma-Biologics, former Cinfa Biotech. He is responsible for the development and implementation of preclinical, clinical and post-approval clinical activities and oversees the pharmacovigilance activities at...

Kaspar Rufibach is a member of Roche's Methods, Collaboration, and Outreach group and located in Basel. He does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and...

Jack earned his Bachelor’s degree in Chemistry from Pomona College in 2000 and his Ph.D. in Chemistry from the University of Wisconsin – Madison in 2006.  His graduate work focused on the development of non-natural, oligomeric (beta-peptide) inhibitors of protein-protein interactions, leading to...

Aaron is CSO of the Biopharma Vertical at Twist Bioscience.  Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice...

Alessandro Satta graduated at Università degli Studi di Milano in 2010 after performing the thesis research on the capability of self-assembling peptides to regenerate nervous cells after spinal cord injury. Then he started working since 2010 in the laboratory of Dr. M.Figini and Dr. S.Canevari in...

Dr Matthieu P Schapranow received a PhD in Software Engineering from University of Potsdam in Germany in 2012. He also received BSc and MSc degrees in Software Engineering, in 2006 and 2008, respectively from the Hasso Plattner Institute (HPI). Currently, he is Program Manager E-Health at the HPI...

Karoline W. Schjetne holds a PhD from Institute of Immunology, University of Oslo, followed by a postdoctoral scholarship where she also hospitalized as visiting researcher at Harvard Medical School. Karoline has worked in both biotech and big pharma industry within the area of immunotherapy and...

Head of Department Biologics-Research, German R&D organization, SanofiDr. Thorsten Schmidt joined Sanofi in 2002. He is currently the Head of the German Biologics Research Platform in the area of protein therapeutics. He is in this role since 2016 and responsible for a team of 60 scientists...

Jacky Schmitt graduated in 1993 in Molecular Biology at the University Louis Pasteur from Strasbourg for a project performed at European Molecular Biology Laboratory in Heidelberg (Germany). Subsequently he performed for 2 years a  post-doctoral fellowship at Max-Planck-Institut für Immunbiologie...

Philip is the Chair of the International Advisory Board for the Alliance for Safe Biologic Medicines, which serves as an authoritative resource center of information for the public, as well as the healthcare and health policy communities, on the issues surrounding biologic medications. Professor...

Darren Schofield, Ph.D., is a Senior Scientist within the Antibody Discovery and Protein Engineering Department, in the R&D BioPharmaceuticals Division at AstraZeneca, UK. He is a protein engineer who leads a small team responsible for the generation of candidate therapeutic biologic drugs...

Dr Nabila SEDDIKI is a Senior Lecturer at the Paris-Est Créteil University (UPEC). She holds an INSERM “Chaire d’Excellence en Immunologie et Maladies Infectieuses”. She joined the Vaccine Research Institute (Créteil, France) end of 2010. Before that she was a Research Fellow at the Centenary...

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano...

Armin Sepp is Scientific Leader and GSK Associate Fellow at the Systems Modeling and Translational Biology group of GlaxoSmithKline where he is providing early stage project support for biotherapeutic projects covering mAbs, antibody fragments as well as cell and gene therapy products. His...

I obtained my PhD in pharmacology from the State University of New York at Buffalo. I had my post-doctoral training in immunology with Dr. Thomas B. Tomasi at Roswell Park Cancer Institute and Dr. Sergio Lira at Mount Sinai School of Medicine.  I joined Novimmune in 2009 and my role has evolved...

Dr Maryam Shariatzadeh is an interdisciplinary bioengineering scientist, and a qualified pharmacist whose project focuses on development of ODE mechanistic modelling for T cell therapy manufacture to offer cost effective solutions in T cells / CAR T cells bioprocessing / process control and...

Mr. Shea is a director in the Biotechnology/Chemical Practice Group at Sterne, Kessler, Goldstein & Fox P.L.L.C., where he has practiced for 20 years.  He specializes in advising biopharmaceutical companies and research institutions on complex legal issues relating to the...

Nigel Shipston is a Director of Program Design at Fujifilm Diosynth Biotechnologies. He is responsible for developing technical scopes of work in proposals for customer programs. He has 29 years’ industrial experience, including at Fujifilm for the past 13 years as a Senior Technical Project Leader ...

Oliver Seifert holds a PhD in Molecular Biology from the University of Stuttgart and he is a Post-Doc at the Institute of Cell Biology and Immunology based at the University of Stuttgart, Germany. Research interests focus on the design and development of multivalent and multispecific antibody...

Dr. Arne Skerra is Full Professor at the Technical University of Munich, Germany, where he heads the Institute of Biological Chemistry. He holds a Diplom degree in Chemistry from the Technical University of Darmstadt and a PhD in Biochemistry from the Ludwig-Maximilians-University Munich. After...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

PhD in Biology,MsC in Biotechnology, MsC in Microbiology andGenetics, MsC in Environmental sciences, BS in Biology and BSin Biotechnology with 20 years of experience in the biotechnologyand bio-pharmaceutical industry. I developed as a professionalin the area of small...

Dr Pietro Sormanni is a Borysiewicz Fellow at the University of Cambridge. His research focuses on the development of innovative data-driven technologies of rational antibody design, to obtain antibodies against targets that have been challenging to access using conventional approaches. At the...

Dr. Spycher is a PSI Founder Fellow at the Paul Scherrer Institute (PSI) Villigen (Switzerland) working on the site-specific modification of native antibodies. He is a co-founder of the PSI spin-off Araris Biotech AG, incorporated in January 2019, that is focused on ADCs and advancing the newly...

Denise Steckel has over 19 years of experience at Genentech in Operations Support, Quality and External Collaborations.   Currently Denise is the Technical Alliance Manager of the Collaboration Alliance Management group.  In this role Denise and her team ensure alignment of all CMC...

Anke is a Senior Researcher in Molecular Design Sciences/Integrated Drug Discovery  at Sanofi R&D providing scientific project support for drug discovery on a broad range of target proteins in the fields of small molecules and biotherapeutics. Anke is profoundly motivated by the human and by...

Stenner Frank, Prof. Dr., M.D.Since 12/2016 Head of the Hematology-Oncology Tumor Center (ZHO)/ BaselSince 06/2012 Senior Physician of Oncology at the University Hospital Basel, Switzerland11/2011-05/2012 Senior Physician of Oncology at the University Hospital Zurich11/2005-11/2011 Attending...

Dr. Pawel Stocki – Director of Research at Ossianix. At Ossianix we are utilising single domain shark antibody fragments to tackle the problem of therapeutic biologics delivery across Blood Brain Barrier. We focus on development and innovation of phage libraries and selection approaches, antibody...

Michael Streit, MD, MBA  is Executive Director and Clinical Development Leader in the Oncology Therapeutic Area of GlaxoSmithKline (GSK) in Collegeville, PA (USA).   Dr. Streit has a strong and diverse background in biomedical sciences. He received his medical degree and training in...

Dr. Strop received his Ph.D. from Caltech, where he elucidated structural mechanism of mechanosensitive ion channels. Afterwards, he moved to Stanford, where he studied proteins involved in synaptic neurotransmission. In 2008, he joined Rinat-Pfizer's protein engineering department where he...

Anish Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical ...

Mathias holds a master’s in engineering in Molecular Biotechnology from Uppsala University and Ph.D. in molecular biology from Karolinska Institutet. He is a co-founder of the cord blood bank Cellaviva, established in 2014, a company that has evolved to NextCell Pharma AB which is developing stem...

Marta Szabat received BEng and BSc degrees from Western University and a PhD in Genetics from the University of British Columbia, Canada. During her post-doctoral studies at the University of British Columbia, she developed high-content, high-throughput screening methods to modulate pancreatic...

Benjamin Szilagyi is leading Medical Data & Information Solutions in Roche Pharma Development. His function is responsible for Medical Data Standards, Internal and External Data Sharing Capabilities, generating and maintaining data analysis tools and programming platforms and managing ETL for...

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in the development of GPCR assay and the...

Huaping Tang is currently a Principal Scientist in the Bioanalytical (BA) Group within the Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) in Merck Research Laboratories. Since joining Merck, Huaping has been focusing on regulated PK and immunogenicity assays for...

Anne-Lise is Senior Research Officer in Analytical Development team, part of Process Sciences department of Glenmark Pharmaceuticals SA biologics R&D centre in La Chaux-de-Fonds, Switzerland. In her position, Anne-Lise has been involved in providing analytical services to various teams, from...

Dr. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio since the formation of the Company in September 2015.  Dr. Tesi has been at the leadership level of biotech companies, both public and private since, 1997.  His industry experience has focused on...

BA diploma with focus on Production and Logistics from the University of Augsburg 3 Years Demand and Forecasting at Fujitsu Siemens Computer5 Years “Seihan” (fully integrated supply chain) Manager at Alpine Electronics7 Years Supply Chain Manager at Teva / Mepha Switzerland Since 2014 Head of...

Rob Thomas is an EPSRC Early Career Fellow and Professor in Manufacturing for Cell Based Therapies at Loughborough University. He leads a team developing the process science and technologies to enable manufacturing of cell based regenerative medicine therapies. The focus is efficient experimental...

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on...

Prof. Dr. Florian Turk is the Global Head Payor Marketing, Sales and Engagement at Sandoz Biopharma. He has more than 15 years of global pharmaceutical and generics industry experience. Prior to joining Sandoz,  Florian held several roles responsible for business-to-business...

Matthew Turner is the Senior Director European Government Affairs Biosimilars at Fresenius Kabi. Following basic lab research in oncology, he joined the pharmaceutical industry 25 years ago.  His career started with the leadership of clinical trials evaluating new drug entities from phase 1 through ...

Janet joined the Clinical Practice Research Datalink (CPRD) in 2015 as Director of the UK Government’s preeminent real-world research service supporting retrospective and prospective public health and clinical studies. Previously Janet spent 6 years as Head of Population Health and Health...

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in hematology/oncology and rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Medicines for Europe’s goal is to improve health by ensuring better access to treatment for patients in Europe and beyond. As Market Access Director for the Generic, Biosimilar and Value-Added medicines groups, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market...

Faidra van der Wal has a rich experience in clinical operations and global trial management.She is a GCDO Trial leader within Janssen, were she has been accountable for phase 3 pivotal studies in immunology.Having worked prior for a CRO as well as for a small biotech company, she has built up a...

Dr Sandrine Vessillier received her PhD in Biochemistry from the University Claude Bernard in Lyon. With a number of years of academic postdoctoral research at the William Harvey Research Institute in London she has developed a broad scientific base in Biochemistry, Enzymology, Immunology and...

Saskia Villinger got her diploma in biochemistry at the University of Frankfurt. She completed her doctoral degree and a post-doc at the Max-Planck-Institute for Biophysical Chemistry in Göttingen. During this period she studied structure, dynamics and interactions of a membrane protein by solution ...

Bernd Voedisch works as a lab head in the Biologics Center of the Novartis Institutes for Biomedical Research in Basel, Switzerland. He is responsible for the generation of protein reagents and recombinant mammalian cell lines facilitating Biologics research projects for various disease...

Johannes vom Berg has been a junior group leader at the Institute of Laboratory Animal Science, University of Zurich, Switzerland since 2015. He also directed the mouse-transgenesis core facility of the University of Zurich from 2014-2018. He studied biology and molecular medicine in Freiburg im...

Ryuta Wada is a research scientist, Pharmaceutical Science & Technology Labs, Pharmaceutical Technology in Astellas Pharma, Inc. JAPAN. He has been working extensively on CMC laboratories, especially specializing in analytical development for mAb biotherapeutics, upstream cell line and process...

As the section leader for the Cytokines and Growth Factors Section, she is responsible for a number of diverse projects in these fields. These include preparation of World Health Organisation WHO international cytokine and growth factor standards and/or reference reagents, development and...

Simon Wandel holds a master in Statistics and a PhD in Medical Statistics/Epidemiology from University of Bern. In 2010, he joined Novartis as statistician. In 2013, he co-founded a start-up specialized for Bayesian statistics (Cogitars GmbH), before rejoining Novartis as Expert Statistical...

Stefan Warmuth, Ph.D. serves as Group Leader CMC and Therapeutic Program Leader at Numab Therapeutics, a Swiss biotech company with partnered as well as proprietary pipeline assets in the field of immuno-oncology and inflammatory diseases. He is responsible for the pharmaceutical development of...

Annemie Wielant has a Biological and Medical European Engineer degree from the Hogeschool Brabant (The Netherlands). She joined UCB in July 2008 in the Analytical Development Sciences for Biologicals department.  She initially worked in the physico/chemical unit before moving to the Bioassay...

Robert leads an Oncology Research department based Granta Park (Cambridge, UK) and oversees pre-clinical oncology biologics research ranging from target identification to candidate drug selection and IND enabling support. Activities focus on utilising the latest biotherapeutic technologies...

Dr. Adriana-Michelle Wolf Pérez is a visiting scientist at the Vendruscolo group in Cambridge,UK, and a scientist at Wren Therapeutics. Her research focuses on the development and validation of innovative technologies for the rational design and  developability prediction of protein...

Florian M. Wurm, trained as Biologist/Molecular/Geneticis. His career involved academic and industrial work: Behringwerke AG, Marburg (1981-1984), Harvard Boston (1984-1985), Genentech Inc, San Francisco (1986-1995), Swiss Federal Institute of Technology, Lausanne (EPFL), (1995-2015), ExcellGene...

Jens Wuerthner is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a licensed physician in Germany, Switzerland and the UK and a fellow of the Faculty of Pharmaceutical Medicine, UK.Dr. Wuerthner...

Research project team lead, and scientist in immunology drug discovery and translational research. Principal investigator and postdoc mentor managing a group of 5 Ph.D. level researchers fordeveloping small molecule compounds, peptides (cystine knot, and macrocyclic peptides), and novel antibodies...

Sijme Zeilemaker is Senior Director Business Development at Immunicum since 2017. Prior to Immunicum, he served as Director Business Development at InteRNA Technologies, a preclinical-stage microRNA oncology biotech, and before that he was Head of Business for 2-BBB Medicines and Business...

Yingnan Zhang, Ph.D. in Biochemistry, is a Senior Scientific Manager at Genentech. She got her Ph.D in the field of enzymology and glycobiology from University of Miami, FL mentored by Dr. Keith Brew. She joined Genentech as a postdoc mentored by Dr. Sachdev Sidhu. She has been involved in many...

Jing joins Refuge Biotechnologies as Chief Business Officer following a wealth of experience in global healthcare transactions and financings. He has spent over a decade in pharmaceutical, biotech and healthcare finance working on a full spectrum of strategic transactions at big cap...

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. During his PhD he spent some time at Scripps Institute, La Jolla (USA) working in the lab of Vaughn...

Maya Zlatanova is a patient advocate and digital health entrepreneur with business development and clinical research regulations background. Maya is a co-founder of FindMeCure (technological startup speeding up clinical trials) and a part of the board of directors at FindMeCure Foundation (a...

Konstantin Zoeller joined Novartis Pharma AG in 2008. His initial focus was on process development R&D to develop purification processes for biologicals supporting early and late phase programs. Since 2009 he has focused in addition on viral safety and, at present, is leading the early phase...